Nicolas Talarek

Dr. Nicolas Talarek

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2003 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SBStéphane Bach
Stéphane Bach
NTNicolas Talarek
Nicolas Talarek
TAThibault Andrieu
Thibault Andrieu
JVJean-Michel Vierfond
Jean-Michel Vierfond
YMYvette Mettey
Yvette Mettey
Marc BlondelMarc Blondel
Marc Blondel

1 January 2013 in Cell Reports
Verified
Journal Article
Open access
SBSéverine Bontron
Séverine Bontron
MJMalika Jaquenoud
Malika Jaquenoud
SVStefania Vaga
Stefania Vaga
NTNicolas Talarek
Nicolas Talarek
BBBernd Bodenmiller
Bernd Bodenmiller
CVClaudio De Virgilio
Claudio De Virgilio
The TORC1 and PKA protein kinases are central elements of signaling networks that regulate eukaryotic cell proliferation in response to growth factors and/or nutrients. In yeast, attenuation of signaling by these kinases following nitrogen and/or carbon limitation activates the protein kinase Rim15, which orchestrates the initiation of a reversible cellular quiescence program to ensure normal chronological life span. The molecular elements linking Rim15 to distal readouts including the expression of Msn2/4- and Gis1-dependent genes involve the endosulfines Igo1/2. Here, we show that Rim15, analogous to the greatwall kinase in Xenopus, phosphorylates endosulfines to directly inhibit the Cdc55-protein phosphatase 2A (PP2A(Cdc55)). Inhibition of PP2A(Cdc55) preserves Gis1 in a phosphorylated state and consequently promotes its recruitment to and activation of transcription from promoters of specific nutrient-regulated genes. These results close a gap in our perception of and delineate a role for PP2A(Cdc55) in TORC1-/PKA-mediated regulation of quiescence and chronological life span.

1 May 2010 in Molecular Cell
Verified
Journal Article
Closed access
NTNicolas Talarek
Nicolas Talarek
ECElisabetta Cameroni
Elisabetta Cameroni
MJMalika Jaquenoud
Malika Jaquenoud
XLXuan Luo
Xuan Luo
SBSéverine Bontron
Séverine Bontron
CVClaudio De Virgilio
Claudio De Virgilio

1 July 2007 in Molecular Cell
Verified
Journal Article
Closed access
VTVibha Taneja
Vibha Taneja
MMMarie-Lise Maddelein
Marie-Lise Maddelein
NTNicolas Talarek
Nicolas Talarek
SSSven Saupe
Sven Saupe
SLSusan W. Liebman
Susan W. Liebman

14 May 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DTDeborah TRIBOUILLARD-TANVIER
Deborah TRIBOUILLARD-TANVIER
SRSuzana Dos Reis
Suzana Dos Reis
FGFabienne Gug
Fabienne Gug
CVCécile Voisset
Cécile Voisset
VBVincent Béringue
Vincent Béringue
Marc BlondelMarc Blondel
Marc Blondel
6-Aminophenanthridine (6AP) and Guanabenz (GA, a drug currently in use for the treatment of hypertension) were isolated as antiprion drugs using a yeast-based assay. These structurally unrelated molecules are also active against mammalian prion in several cell-based assays and in vivo in a mouse model for prion-based diseases. Here we report the identification of cellular targets of these drugs. Using affinity chromatography matrices for both drugs, we demonstrate an RNA-dependent interaction of 6AP and GA with the ribosome. These specific interactions have no effect on the peptidyl transferase activity of the ribosome or on global translation. In contrast, 6AP and GA specifically inhibit the ribosomal RNA-mediated protein folding activity of the ribosome. 6AP and GA are therefore the first compounds to selectively inhibit the protein folding activity of the ribosome. They thus constitute precious tools to study the yet largely unexplored biological role of this protein folding activity.

1 May 2006 in Methods
Verified
Journal Article
Closed access
SBStéphane Bach
Stéphane Bach
DTDéborah Tribouillard
Déborah Tribouillard
NTNicolas Talarek
Nicolas Talarek
NDNathalie Desban
Nathalie Desban
FGFabienne Gug
Fabienne Gug
Marc BlondelMarc Blondel
Marc Blondel